Moxifloxacin

Introduction Overview

Generic Name

Moxifloxacin

Brand Name

Avelox

Dosage Form

Oral tablets, IV injection for infusion

Drug Class

Quinolones (Fluoroquinolone antibiotic)

Pharmacokinetics

Absorption:
Moxifloxacin exhibits high oral bioavailability ranging from 86–92%, which supports its effective use in both oral and intravenous (IV) formulations. Peak plasma concentrations are typically reached between 0.5 to 4 hours post-administration, with steady-state concentrations attained after at least three days of consistent dosing. Food, including high-fat meals or yogurt, does not significantly affect the absorption of moxifloxacin, allowing flexible administration with or without meals. However, oral administration must be timed carefully to avoid coadministration with agents that chelate or bind moxifloxacin, such as aluminum- or magnesium-containing antacids, iron, zinc, sucralfate, or buffered didanosine, as these can markedly reduce absorption. It is recommended to administer moxifloxacin at least 4 hours before or 8 hours after these agents to ensure optimal bioavailability.

Distribution:
Moxifloxacin is widely distributed throughout the body, penetrating well into various tissues and fluids including saliva, nasal and bronchial secretions, sinus mucosa, skin blister fluid, subcutaneous tissue, skeletal muscle, and abdominal tissues/fluids. This broad tissue distribution contributes to its utility against respiratory, skin, and intra-abdominal infections. Plasma protein binding is moderate (30–50%), allowing a substantial free drug fraction to exert antibacterial activity. Although animal data suggests distribution into cerebrospinal fluid (CSF) and milk, the extent of penetration into human CSF remains less defined but is adequate to be considered in some CNS infections. Moxifloxacin crosses biological membranes effectively, which also facilitates its activity against intracellular pathogens such as Chlamydia and Mycoplasma species.

Metabolism:
Approximately 52% of an administered dose (oral or IV) of moxifloxacin undergoes metabolic transformation mainly through phase II conjugation pathways including glucuronidation and sulfation. These metabolites are microbiologically inactive. Importantly, moxifloxacin is not metabolized by cytochrome P450 (CYP) isoenzymes, and it does not inhibit major CYP enzymes (e.g., CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2), minimizing its potential for CYP-mediated drug-drug interactions. The metabolic clearance via conjugation pathways contributes significantly to the drug's elimination.

Elimination:
Moxifloxacin elimination occurs via both renal and fecal routes. Approximately 45% of the dose is excreted unchanged, with around 20% recovered in urine and 25% in feces. Overall excretion of unchanged drug plus metabolites accounts for 96% of the administered dose. The elimination half-life in adults with normal renal and hepatic function ranges from approximately 11.5 to 15.6 hours orally and 8.2 to 15.4 hours by IV administration, permitting once-daily dosing. Pharmacokinetic profiles remain consistent across geriatric populations and patients with varying degrees of renal impairment, with no dose adjustments required even in severe renal dysfunction or dialysis. Patients with hepatic impairment show increased conjugate metabolites concentrations, but moxifloxacin plasma levels are generally unaltered, and dosage adjustments are not required. Thus, moxifloxacin has favorable pharmacokinetic properties allowing flexible administration in diverse patient populations.

Dosage Forms

Available Dosage Forms:
Moxifloxacin is available in the following commercial formulations:
- Oral tablets, film-coated: 400 mg of moxifloxacin hydrochloride (e.g., Avelox, Moxifloxacin Hydrochloride Tablets).
- Parenteral: Injection for intravenous (IV) infusion containing 400 mg of moxifloxacin in 0.8% sodium chloride solution in single-use flexible containers (e.g., Avelox I.V., Moxifloxacin Hydrochloride Injection for IV Infusion).

Dosages for Adults and Adolescents:
The adult dosage of moxifloxacin is generally 400 mg once daily, administered orally or intravenously, with identical dosing for both routes and no requirement for dosage adjustment when switching between oral and IV administration. The indications and durations are:
- Acute bacterial sinusitis: 400 mg once daily for 10 days.
- Acute bacterial exacerbations of chronic bronchitis: 400 mg once daily for 5 days.
- Community-acquired pneumonia (CAP): 400 mg once daily for 7 to 14 days.
- Uncomplicated skin and skin structure infections: 400 mg once daily for 7 days.
- Complicated skin and skin structure infections: 400 mg once daily for 7 to 21 days.
- Complicated intra-abdominal infections: initiate with 400 mg IV once daily, then switch to oral 400 mg once daily; total duration generally 5 to 14 days.
- GI infections such as campylobacteriosis, salmonella gastroenteritis, and shigellosis in HIV-infected adults: 400 mg once daily with variable treatment durations depending on infection severity and immune status.
- Anthrax (postexposure prophylaxis, cutaneous and systemic forms): 400 mg once daily oral or IV, with oral continuation for 60 days post exposure in biological warfare or bioterrorism contexts.
- Mycobacterial infections including active tuberculosis and MAC infections: 400 mg once daily; always as part of combination regimens.
- Nongonococcal urethritis (persistent/recurrent cases): 400 mg once daily for 7 days orally.
- Plague treatment and prophylaxis: 400 mg once daily orally or IV for 10–14 days.

Pediatric Dosages:
Moxifloxacin is not generally approved for pediatric use due to safety concerns involving joint toxicity, but off-label dosing for systemic anthrax in neonates to adolescents is as follows:
- Preterm neonates (≤4 weeks, gestational age 32–37 weeks): 5 mg/kg IV once daily.
- Full-term neonates (≤4 weeks): 10 mg/kg IV once daily.
- Infants 3 months to <2 years: 6 mg/kg (max 200 mg) IV every 12 hours.
- Children 2–5 years: 5 mg/kg (max 200 mg) IV every 12 hours.
- Children 6–11 years: 4 mg/kg (max 200 mg) IV every 12 hours.
- Adolescents 12–17 years: 4 mg/kg (max 200 mg) every 12 hours if weight <45 kg; 400 mg once daily if ≥45 kg.

Specific Patient Populations:
- Renal impairment (including dialysis): No dosage adjustments required.
- Hepatic impairment (mild to severe, Child-Pugh classes A, B, C): Dosage adjustments not necessary but caution advised.
- Geriatric patients: No dosage reduction needed; increased risk of certain adverse effects warrants caution.
- Pregnancy and lactation: Use only if benefits justify risk; limited human data.
- When administered orally, moxifloxacin tablets should be taken without regard to meals but separated from multivitamins, antacids, iron, zinc, or sucralfate by at least 4 to 8 hours to avoid decreased absorption.

Administration Notes:
- IV infusion to be administered slowly over 1 hour; avoid rapid infusion.
- Moxifloxacin IV solution is provided premixed, should not be diluted or mixed with other drugs, and must be inspected for particulates.
- Oral therapy preferred when feasible, with IV reserved for patients unable to take oral medication or when clinical advantage exists.

Mechanism Of Action

Moxifloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic whose primary mechanism of action involves inhibition of bacterial type II topoisomerases—namely DNA gyrase and topoisomerase IV. These enzymes regulate the supercoiling and untangling of bacterial DNA, essential steps for DNA replication, transcription, repair, and recombination. By selectively targeting these enzymes, moxifloxacin disrupts crucial processes within bacterial cells, leading to inhibition of DNA synthesis and cell death.

At the molecular level, moxifloxacin forms stable complexes with DNA and bacterial topoisomerases following DNA strand cleavage. This stabilization prevents religation of DNA breaks, causing accumulation of DNA damage and double-strand breaks. Such DNA fragmentation triggers bacterial cell death through irreversible damage. Moxifloxacin exhibits enhanced affinity and dual targeting capability, binding effectively to both DNA gyrase—more relevant in gram-negative bacteria—and topoisomerase IV, which is more significant in gram-positive cocci. This dual enzyme inhibition contributes to moxifloxacin’s potent and broad-spectrum bactericidal activity, including efficacy against multidrug-resistant pneumococci.

Cellularly, moxifloxacin’s interference with DNA processes leads to rapid bactericidal effects as cells accumulate lethal DNA breaks. Its activity extends against gram-positive aerobes, some gram-negative aerobes, anaerobes, and atypical bacteria such as Mycoplasma and Chlamydia species. It also demonstrates clinical utility against select mycobacterial species, including Mycobacterium tuberculosis and MAC, by similar inhibition of mycobacterial DNA topoisomerase enzymes.

Clinically, moxifloxacin’s enhanced activity against resistant pathogens, rapid bacterial kill kinetics, and prolonged post-antibiotic effect contribute to its utility in respiratory, skin, intra-abdominal, and certain systemic infections. Compared to other fluoroquinolones like ciprofloxacin and levofloxacin, moxifloxacin displays superior activity against gram-positive cocci, particularly Streptococcus pneumoniae, including multidrug-resistant strains, while retaining activity against a broad range of other pathogens. However, resistance can develop through mutations in the genes encoding DNA gyrase or topoisomerase IV, reduced outer membrane permeability, or increased efflux, albeit generally occurring slowly.

Extensive clinical studies and microbiological data support moxifloxacin’s role as an efficacious agent against community-acquired respiratory infections, complicated intra-abdominal infections, and atypical pathogens. Its unique pharmacodynamic profile combining dual enzyme targeting, extensive tissue penetration, and a favorable pharmacokinetic half-life facilitates once-daily dosing, enhancing compliance and clinical outcomes.

Pharmacological Actions

Bactericidal activity through inhibition of bacterial DNA gyrase and topoisomerase IV enzymes.
Broad-spectrum antibacterial activity against gram-positive and gram-negative aerobes, anaerobes, and certain atypical and mycobacterial species.
Inhibition of bacterial DNA replication and transcription, causing DNA strand breaks and bacterial cell death.
Effective against multidrug-resistant Streptococcus pneumoniae and methicillin-susceptible Staphylococcus aureus.
Activity includes respiratory pathogens such as Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Demonstrated efficacy against anaerobic bacteria including Bacteroides fragilis and Clostridium perfringens.
Exhibits activity against mycobacteria such as Mycobacterium tuberculosis, Mycobacterium avium complex, and Mycobacterium kansasii.
Not metabolized by cytochrome P450 enzymes, minimizing CYP-mediated drug interactions.
Possesses excellent tissue penetration, including respiratory secretions, skin, and abdominal tissues.
Extended half-life allows once-daily dosing, improving patient adherence.
Limited potential for pharmacokinetic interactions due to minimal plasma protein binding (30–50%) and predominant excretion via conjugation and feces.
Activity results in suppression of resistant bacterial mutant selection due to dual target enzyme inhibition.
In vitro resistance develops slowly through multiple-step mutations, reducing risk of rapid resistance emergence.
Demonstrates rapid bactericidal killing action with a post-antibiotic effect, beneficial for clinical efficacy.
Steady-state plasma concentrations attained after multiple doses, supporting consistent antibacterial effect.

Therapeutic Or Clinical Uses

Treatment of acute bacterial sinusitis caused by susceptible Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis when no alternative treatments available.
Management of acute bacterial exacerbations of chronic bronchitis due to susceptible respiratory pathogens under restricted conditions.
Treatment of community-acquired pneumonia (CAP), including multidrug-resistant Streptococcus pneumoniae and atypical pathogens such as Mycoplasma pneumoniae.
Treatment of uncomplicated and complicated skin and skin structure infections caused by methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, and Enterobacter cloacae.
Complicated intra-abdominal infections involving polymicrobial flora including anaerobes like Bacteroides fragilis.
Alternative agent for endocarditis caused by HACEK group organisms in patients unable to tolerate cephalosporins (off-label use).
Treatment of gastrointestinal infections such as campylobacteriosis, salmonella gastroenteritis, and shigellosis in HIV-infected patients (off-label).
Postexposure prophylaxis and treatment of anthrax following exposure to aerosolized Bacillus anthracis spores, including systemic and cutaneous forms in bioterrorism scenarios.
Alternative treatment for meningitis caused by certain gram-positive and gram-negative bacteria when standard therapies are unsuitable (off-label).
Second-line agent in combination regimens for multidrug-resistant tuberculosis and disseminated Mycobacterium avium complex infections.
Treatment of nongonococcal urethritis, especially for persistent or recurrent cases after first-line therapy failure (off-label).
Treatment and prophylaxis of plague caused by Yersinia pestis in naturally occurring or bioterrorism contexts.
Used with caution in off-label applications such as nosocomial pneumonia and other resistant infections as guided by clinical judgment and susceptibility.
Important option for patients with contraindications or intolerance to first-line agents in specified infectious diseases.
Empiric therapy agent where guided by local susceptibility patterns and clinical guidelines such as IDSA.

Side Or Adverse Effects

Tendinitis and tendon rupture, potentially disabling and irreversible, with increased risk in elderly patients over 60 years, corticosteroid users, and transplant recipients.
Peripheral neuropathy presenting as sensory or sensorimotor axonal polyneuropathy with symptoms like pain, burning, tingling, numbness, or weakness; may be irreversible.
Central nervous system effects including seizures, dizziness, headache, confusion, hallucinations, psychiatric disturbances (anxiety, psychosis, agitation), increased intracranial pressure (pseudotumor cerebri).
Hypersensitivity reactions ranging from rash, urticaria, and pruritus to severe anaphylaxis and life-threatening conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis.
Phototoxicity/photosensitivity reactions manifesting as severe sunburn-like eruptions on sun-exposed skin areas.
Gastrointestinal disturbances including nausea, diarrhea, vomiting, and abdominal discomfort; potential for Clostridioides difficile-associated diarrhea and colitis.
Cardiac adverse effects such as QT interval prolongation, which may precipitate torsades de pointes and other ventricular arrhythmias.
Hepatotoxicity including acute liver injury, hepatitis, jaundice, and rare fatal hepatic failure cases.
Hypoglycemia and hyperglycemia events, especially in diabetics receiving antidiabetic medications; hypoglycemic coma reported rarely.
Musculoskeletal toxicity demonstrated by arthropathy and osteochondrosis in immature animals; safety in pediatric patients not established.
Injection site reactions during IV administration such as phlebitis and pain.
Rare hematologic adverse reactions including anemia, thrombocytopenia, leukopenia, agranulocytosis, and pancytopenia.
Aortic aneurysm and dissection risk elevated, particularly in patients with predispositions such as hypertension or connective tissue disorders.
Potential exacerbation of myasthenia gravis symptoms, including respiratory muscle weakness and fatal respiratory failure.
Other reactions include fever, vasculitis, allergic pneumonitis, interstitial nephritis, and serum sickness-like phenomena.

Precautions

Use moxifloxacin only for infections proven or strongly suspected to be caused by susceptible bacteria to reduce resistance development.
Avoid use in patients with a history of hypersensitivity to moxifloxacin or other quinolones.
Monitor elderly patients closely due to increased risk of tendinitis, tendon rupture, QT prolongation, and aortic aneurysm.
Discontinue immediately at first sign of serious adverse reactions such as tendon pain, neuropathy symptoms, severe rash, or psychiatric events.
Avoid concomitant use with other drugs prolonging QT interval and correct electrolyte imbalances prior to administration.
Use with caution in patients with CNS disorders or seizure risk; close monitoring advised.
Patients with hepatic impairment require cautious use due to potential QT prolongation risk and altered metabolite levels.
Hydrate adequately during therapy to prevent crystalluria and renal adverse effects.
Inform patients to avoid sun exposure and use protective measures to prevent photosensitivity reactions.
Exercise caution when prescribing to patients with myasthenia gravis due to risk of exacerbation.
Carefully monitor blood glucose in diabetic patients treated with moxifloxacin.
Avoid unnecessary or prolonged use, particularly in self-limiting infections such as acute bacterial sinusitis or bronchitis when other options exist.
Not recommended for routine use in children or adolescents under 18 years except in specific circumstances where benefits outweigh risks.
Discontinue therapy upon signs of Clostridioides difficile-associated diarrhea and institute appropriate measures promptly.
Monitor for signs of aortic aneurysm or dissection, especially in susceptible individuals.

Warnings

Disabling and potentially irreversible serious adverse reactions including tendinitis, tendon rupture, peripheral neuropathy, and CNS effects may occur together; discontinue immediately if symptoms develop.
Tendinitis and tendon rupture risk higher in elderly patients, corticosteroid users, and transplant recipients; can occur shortly after initiation or months after discontinuation.
Peripheral neuropathy symptoms may be rapid in onset and irreversible; immediate cessation required if symptoms arise.
CNS adverse reactions including seizures, psychosis, hallucinations, and increased intracranial pressure can occur, sometimes after first dose.
Use contraindicated in patients with history of myasthenia gravis due to risk of exacerbation and respiratory compromise.
Serious hypersensitivity reactions, including anaphylaxis and fatal reactions, may occur even with first dose.
Photosensitivity and phototoxicity may cause severe sunburn-like skin reactions; minimize exposure to UV light.
QT interval prolongation may lead to torsades de pointes and ventricular arrhythmias; dose and infusion rate should not be exceeded.
Risk of aortic aneurysm and dissection increased, particularly within 2 months of systemic fluoroquinolone exposure; avoid in at-risk patients.
Blood glucose disturbances including severe hypoglycemia and hyperglycemia reported, some fatal.
Use with caution in hepatic impairment; metabolic disturbances may increase QT prolongation risk.
Potential for Clostridioides difficile-associated diarrhea including fatal colitis; consider diagnosis if diarrhea develops during or after therapy.
Safety and efficacy in pediatric patients under 18 not established; risk of arthropathy and osteochondrosis based on animal studies.
Not to be used intramuscularly, subcutaneously, intrathecally, or intraperitoneally.
Discontinue at first signs of rash, jaundice, or other signs of hypersensitivity or hepatotoxicity.

Contraindication

Known hypersensitivity to moxifloxacin or other quinolones.
History of tendinitis or tendon rupture related to fluoroquinolone use.
Patients with myasthenia gravis due to risk of exacerbation and respiratory failure.
Concomitant use with drugs known to prolong QT interval in patients with known prolongation or history of torsades de pointes.
Use in pediatric patients under 18 years except in specific, justified clinical circumstances due to risk of musculoskeletal toxicity.
Patients with aortic aneurysm or at increased risk of aortic aneurysm or dissection unless no alternatives exist.
Use for treatment of acute bacterial sinusitis or acute bacterial exacerbations of chronic bronchitis when other treatment options are available.
Known intolerance to any excipients or formulations of moxifloxacin.
Use via routes other than oral or intravenous infusion (e.g., intramuscular, subcutaneous) is contraindicated.
Patients with known electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) predisposing to arrhythmia unless corrected.

Drug Interactions

Agents that prolong QT interval (e.g., class IA antiarrhythmics like quinidine and procainamide, class III agents like amiodarone and sotalol, erythromycin, antipsychotics, tricyclic antidepressants) may have additive effects increasing arrhythmia risk.
Antacids containing aluminum or magnesium significantly decrease oral moxifloxacin absorption; administer moxifloxacin at least 4 hours before or 8 hours after antacids.
Iron and zinc supplements reduce absorption when given concomitantly; separate dosing similarly by at least 4 to 8 hours.
Sucralfate impairs oral absorption; dose separation necessary.
Oral anticoagulants like warfarin may have enhanced anticoagulant effects; monitor PT/INR closely.
Antidiabetic agents (sulfonylureas, insulin) interactions may cause hypo- or hyperglycemia; careful glucose monitoring required.
Corticosteroids concomitant use increases risk of tendinitis and tendon rupture.
No clinically significant pharmacokinetic interactions with cyclosporine, digoxin, morphine, atenolol, calcium supplements, or most azole antifungals (e.g., itraconazole).
Didanosine buffered pediatric oral solution reduces moxifloxacin absorption; separate administration by dosing intervals.
Nonsteroidal anti-inflammatory agents may increase risk of CNS stimulation or seizures, observed with other fluoroquinolones.
Probenecid and ranitidine have no significant interactions with moxifloxacin pharmacokinetics.
Moxifloxacin neither induces nor inhibits major CYP450 isoenzymes, reducing likelihood of CYP-mediated drug interactions.
Multivitamins containing iron or zinc reduce absorption; dosing separation required.
No dosage adjustments required when coadministered with digoxin despite transient increases in digoxin concentrations.
No significant effect on oral contraceptive pharmacokinetics or efficacy.

Preparations Of The Drug

Moxifloxacin hydrochloride 400 mg film-coated oral tablets (Brand: Avelox, generic Moxifloxacin Hydrochloride Tablets) manufactured by Bayer.
Moxifloxacin hydrochloride 400 mg injection premixed for intravenous infusion in 0.8% sodium chloride single-use flexible containers (Brand: Avelox I.V., generic Moxifloxacin Hydrochloride Injection for IV Infusion) manufactured by Bayer.
Excipients in commercial formulations may have clinically relevant effects; refer to specific product labeling for detailed information.
Premixed IV solution is preservative-free and must be discarded if unused.
Store oral tablets at controlled room temperature (25°C, tolerable 15–30°C) avoiding high humidity.
IV injection also stored at 25°C (tolerable 15–30°C) and should not be refrigerated.
IV solution compatible with Dextrose 5% or 10% in water, lactated Ringer's injection, and 0.9% sodium chloride.
IV solution compatible with cangrelor tetrasodium, ceftaroline fosamil, doripenem, hydroxyethyl starch 130/0.4 in sodium chloride, and vasopressin.
Do not admix IV moxifloxacin with other drugs or administer simultaneously through the same infusion tubing.
Inspect IV solution visually prior to administration; should appear yellow and free of particulate matter.
Single-use IV containers only; discard unused portions after administration.
Patient information leaflets and medication guides accompany all preparations advising on dosing, precautions, and potential adverse effects.